IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Condition(s):Advanced MelanomaLast Updated:March 7, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Advanced MelanomaLast Updated:March 7, 2024Recruiting
Condition(s):Hepatitis B, ChronicLast Updated:March 19, 2024Recruiting
Condition(s):Advanced MelanomaLast Updated:March 7, 2024Recruiting
Condition(s):Uveal MelanomaLast Updated:January 21, 2022Available
Condition(s):Select Advanced Solid TumorsLast Updated:September 28, 2023Recruiting
Condition(s):Select Advanced Solid TumorsLast Updated:March 7, 2024Terminated
Condition(s):Select Advanced Solid TumorsLast Updated:March 11, 2022Terminated
Condition(s):Uveal MelanomaLast Updated:March 8, 2024Active, not recruiting
Condition(s):Malignant MelanomaLast Updated:July 27, 2020Terminated
Condition(s):Uveal MelanomaLast Updated:March 21, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.